NZ783034A - Compositions and methods for decreasing tau expression - Google Patents

Compositions and methods for decreasing tau expression

Info

Publication number
NZ783034A
NZ783034A NZ783034A NZ78303416A NZ783034A NZ 783034 A NZ783034 A NZ 783034A NZ 783034 A NZ783034 A NZ 783034A NZ 78303416 A NZ78303416 A NZ 78303416A NZ 783034 A NZ783034 A NZ 783034A
Authority
NZ
New Zealand
Prior art keywords
oligonucleotide
nucleotides
seq
moe
mcgt
Prior art date
Application number
NZ783034A
Other versions
NZ783034B2 (en
Inventor
Ofengeim Manuela Polydoro
Jan Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority claimed from NZ743231A external-priority patent/NZ743231B2/en
Publication of NZ783034A publication Critical patent/NZ783034A/en
Publication of NZ783034B2 publication Critical patent/NZ783034B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided herein are compositions and methods for decreasing tau mRNA and protein expression. These compositions and methods are useful in treating tau-related diseases and disorders.

Claims (22)

CLAIMS :
1. An oligonucleotide comprising a nucleobase sequence that has at least 90% sequence identity to any of the ing nucleobase sequences: G*G*T*T*G*ACATCGTCTGC*C*T*G*T* (SEQ ID NO: 208) or G*G*T*T*G*A mCAT mCGT mCTG mC* mC*T*G*T* (SEQ ID N° 285); wherein C in any of the nucleobase sequences is either cytosine or 5-methylcytosine, and mC is 5-methylcytosine and wherein at least one nucleotide of the oligonucleotide has a 2’- cation, wherein the nucleotides with * have a 2’-O-MOE modification and the nucleotides without * are 2’-deoxynucleosides.
2. The oligonucleotide of claim 1, wherein the internucleoside linkage of the oligonucleotide is either phosphodiester or phosphorothioate linkage.
3. The oligonucleotide of claim 1 or 2, n the oligonucleotide decreases tau mRNA or protein sion independent of RNAse H.
4. The oligonucleotide of any one of claims 1-3, wherein the oligonucleotide ses a base sequence that has at least 95% sequence identity to any of the following nucleobase sequences: G*G*T*T*G*ACATCGTCTGC*C*T*G*T* (SEQ ID NO: 208) or T*G*A mCAT mCGT mCTG mC* mC*T*G*T* (SEQ ID N° 285).
5. The oligonucleotide of any one of claims 1-4, wherein the oligonucleotide comprises any of the following nucleobase sequences: G*G*T*T*G*ACATCGTCTGC*C*T*G*T* (SEQ ID NO: 208) or G*G*T*T*G*A mCAT mCGT mCTG mC* mC*T*G*T* (SEQ ID N° 285).
6. The oligonucleotide of any one of claim 1-5, wherein the oligonucleotide consists of any of the following nucleobase sequences G*G*T*T*G*ACATCGTCTGC*C*T*G*T* (SEQ ID NO: 208) or G*G*T*T*G*A mCAT mCGT mCTG mC* mC*T*G*T*(SEQ ID N° 285).
7. The oligonucleotide of any one of claims 1-6, wherein the internucleoside linkage of the oligonucleotide is phosphorothioate linkage.
8. The oligonucleotide of any one of claims 1-7, wherein the oligonucleotide comprises at least five contiguous 2’-deoxynucleosides.
9. The oligonucleotide of any one of claims 1-8, wherein the oligonucleotide decreases tau mRNA or protein expression by activating RNAse H.
10. The oligonucleotide of any one of claims 1-9, n each C in any of the nucleobase sequences is ylcytosine.
11. The oligonucleotide of any one of claims 1-10, n the oligonucleotide comprises one or more 5-methylcytosines.
12. The ucleotide of anyone of claims 1-11, wherein each nucleotide of the oligonucleotide has a 2’-modification.
13. The oligonucleotide of any one of claims 1-12, wherein the oligonucleotide comprises 12 to 30 nucleobases. or comprises 12 to 25 nucleobases or comprises 15 to 20 nucleobases.
14. The oligonucleotide of any one of claims 1-13, wherein the 2’-modification is ed from the group consisting of oro, 2’-deoxy-2’-fluoro, 2’-O-methyl, 2’-O- methoxyethyl (2’-O-MOE), 2’-O-aminopropyl (2’-O-AP), 2’-O-dimethylaminoethyl (2’-ODMAOE ), 2’-O-dimethylaminopropyl (2’-O-DMAP), 2’-O-dimethylaminoethyloxyethyl (2’- O-DMAEOE), and 2’-O-N-methylacetamido (2’-O-NMA).
15. The oligonucleotide of any one of claims 1-14, wherein the 2’-modification is 2’- O-methoxyethyl (2’-O-MOE).
16. The oligonucleotide of any one of claims 1-15, wherein the oligonucleotide is capable of decreasing tau mRNA or protein expression level by at least 30% in vitro.
17. The oligonucleotide of any one of claims 1-16, wherein the oligonucleotide is capable of decreasing tau mRNA or protein expression level by at least 30% in vivo.
18. The oligonucleotide of any one of claims 1-17, wherein the first to fifth nucleotides each se a 2’-O-MOE modified nucleoside, wherein the sixth to fifteenth nucleotides each comprise a xynucleoside, and wherein the sixteenth to twentieth nucleotides each comprise a 2’-O-MOE modified nucleoside.
19. The oligonucleotide of claim 18, wherein the first to fifth nucleotides each comprise a 2’-O-MOE modified nucleoside, wherein the sixth to nth nucleotides each comprise a 2’-deoxynucleoside, and wherein the sixteenth to twentieth nucleotides each comprise a 2’-O-MOE modified nucleoside
20. An oligonucleotide consisting of a nucleobase sequence of: G*G*T*T*G*A mCAT mCGT mCTG mC* mC*T*G*T* (SEQ ID NO 285), n the nucleotides with * are 2’-O-MOE modified nucleotide, wherein mC is 5-methylcytosine, the nucleotides without * are 2’-deoxynucleosides and n internucleoside linkages are phosphorothioate.
21. An ucleotide consisting of a nucleobase ce of: G*G*T*T*G*ACATCGTCTGC*C*T*G*T*(SEQ ID NO: 208), wherein the nucleotides with * are 2’-O-MOE modified nucleotide, wherein C is either cytosine or 5-methylcytosine, the nucleotides without * are xynucleosides and wherein internucleoside es are phosphorothioate.
22. A composition comprising the oligonucleotide of any one of claims 1-21 and a pharmaceutically acceptable carrier. ..\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\kkkkk\kkkkkkkkkkkkkkkkkbv {3333‘ a.3 ‘\..\V\«\x‘I \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\‘.\\\\\\\\\\\\\\\\‘ \\-x.m“\x“.““x“.V“...xxx“ ““mm. m\“\“\““\““\m \M\\\\\\\\\\\\\\\\\\\\\
NZ783034A 2016-12-19 Compositions and methods for decreasing tau expression NZ783034B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562270165P 2015-12-21 2015-12-21
NZ743231A NZ743231B2 (en) 2016-12-19 Compositions and methods for decreasing tau expression

Publications (2)

Publication Number Publication Date
NZ783034A true NZ783034A (en) 2025-07-25
NZ783034B2 NZ783034B2 (en) 2025-10-29

Family

ID=

Also Published As

Publication number Publication date
JP2019500428A (en) 2019-01-10
EP4678748A2 (en) 2026-01-14
JP2022065096A (en) 2022-04-26
MY191737A (en) 2022-07-13
PL3394259T3 (en) 2024-07-22
IL260124A (en) 2018-07-31
MA44426B1 (en) 2024-05-31
RS65535B1 (en) 2024-06-28
CU20180065A7 (en) 2018-11-06
CU24574B1 (en) 2022-01-13
HRP20240672T1 (en) 2024-08-16
EA201891468A1 (en) 2018-12-28
KR20250112919A (en) 2025-07-24
CN116218848A (en) 2023-06-06
IL305866B1 (en) 2024-08-01
JP7594557B2 (en) 2024-12-04
DOP2018000151A (en) 2018-09-15
MX2018007726A (en) 2018-08-15
JOP20200228A1 (en) 2020-09-13
AU2016376034B2 (en) 2020-12-03
RU2018126545A3 (en) 2020-10-12
CL2019000149A1 (en) 2019-06-07
RU2021112980A (en) 2021-05-28
SG10201913434PA (en) 2020-03-30
TWI787163B (en) 2022-12-21
CA3312277A1 (en) 2026-06-21
IL305866A (en) 2023-11-01
JP2025026976A (en) 2025-02-26
CN109072237A (en) 2018-12-21
FI3394259T3 (en) 2024-05-24
KR102834468B1 (en) 2025-07-15
JP7027328B2 (en) 2022-03-01
CN109072237B (en) 2022-12-16
SI3394259T1 (en) 2024-07-31
DK3394259T3 (en) 2024-05-27
US11473083B2 (en) 2022-10-18
TW201733597A (en) 2017-10-01
UY37038A (en) 2017-07-31
RU2021112980A3 (en) 2021-12-28
IL296844B2 (en) 2024-04-01
AU2016376034A1 (en) 2018-07-05
EA202091865A1 (en) 2021-01-29
EP3394259B1 (en) 2024-02-28
IL296844B1 (en) 2023-12-01
CA3008094A1 (en) 2017-06-29
MX2023008211A (en) 2023-07-18
HK1254822A1 (en) 2019-07-26
HUE066548T2 (en) 2024-08-28
US20170175116A1 (en) 2017-06-22
ZA201803661B (en) 2024-08-28
CR20200609A (en) 2021-02-17
TWI834177B (en) 2024-03-01
TW202311530A (en) 2023-03-16
CL2019003420A1 (en) 2020-05-15
AU2020267282B2 (en) 2023-05-18
KR20180089517A (en) 2018-08-08
US20260176634A1 (en) 2026-06-25
WO2017109679A1 (en) 2017-06-29
SA518391831B1 (en) 2022-08-16
US20220411796A1 (en) 2022-12-29
CL2018001652A1 (en) 2018-08-10
EP4406541A2 (en) 2024-07-31
EP3394259A1 (en) 2018-10-31
EP4748380A2 (en) 2026-05-27
PH12018501207B1 (en) 2024-02-23
BR112018012304A2 (en) 2019-02-05
EA036417B1 (en) 2020-11-09
IL296844A (en) 2022-11-01
MA71468A (en) 2025-04-30
AU2020267282A1 (en) 2020-12-10
JP7899282B2 (en) 2026-08-03
EP4406541A3 (en) 2024-10-16
LT3394259T (en) 2024-06-10
PE20181448A1 (en) 2018-09-12
SV2018005714A (en) 2018-09-10
JP2021118732A (en) 2021-08-12
IL305866B2 (en) 2024-12-01
RU2018126545A (en) 2020-01-23
RU2747734C2 (en) 2021-05-13
ECSP18050575A (en) 2018-07-31
EP4678748A3 (en) 2026-05-27
PH12018501207A1 (en) 2019-02-11
JO3790B1 (en) 2021-01-31
SG11201804704PA (en) 2018-07-30
PE20241069A1 (en) 2024-05-13
NZ743231A (en) 2025-07-25
ES2984631T3 (en) 2024-10-30
PT3394259T (en) 2024-05-20
AR107579A1 (en) 2018-05-16
CO2018006297A2 (en) 2018-07-10

Similar Documents

Publication Publication Date Title
EP4455285A3 (en) Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
WO2020219981A3 (en) Oligonucleotide compositions and methods of use thereof
FI4220360T3 (en) OLIGONUCLEOTIDES FOR PATERNAL UBE3A EXPRESSION
EP4527459A3 (en) Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
JP2013226147A5 (en)
JP2018138020A (en) Polycomb-associated non-coding rnas
JP2018512041A5 (en)
JP2016116520A5 (en)
JP2018512110A5 (en)
MX2010009195A (en) Ultra-small rnas as toll-like receptor-3 antagonists.
JP2016522674A5 (en)
WO2014025887A1 (en) Selective reactivation of genes on the inactive x chromosome
WO2005089287A3 (en) Methods and compositions for the specific inhibition of gene expression by double-stranded rna
EA201100813A1 (en) PHARMACEUTICAL COMPOSITION
JP2015523853A5 (en)
JP2016521556A5 (en)
RU2014121304A (en) INHIBITION OF EXPRESSION OF VIRAL GENES
PH12021551025A1 (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
JP2023503635A (en) Methods of synthesizing RNA molecules
PE20242176A1 (en) PMP22-TARGETING COMPOUNDS FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH DISEASE
PH12021551544A1 (en) Oligomeric nucleic acid molecule and application thereof
WO2021262919A3 (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
KR20150130444A (en) MicroRNA-BASED APPROACH TO TREATING MALIGNANT PLEURAL MESOTHELIOMA
NZ783034B2 (en) Compositions and methods for decreasing tau expression
JP2020515625A5 (en)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 DEC 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20251124